Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | LCT | P09848 | 2/20 | 0.39 |
| ▸ | SI | P14410 | 2/20 | 0.39 |
| ▸ | UGCG | Q16739 | 2/20 | 0.39 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | FABP7 | O15540 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL9538327 | 0.88 | TACR1 (0.56) | TACR1DPP4CHRNB2CHRNA4PDCD1 | |
| SCHEMBL336977 | 0.87 | TACR1 (0.62) | TACR1DPP4CHRNB2CHRNA4PDCD1 | |
| SCHEMBL21796063 | 0.87 | TACR1 (0.38) | TACR1DPP4CHRNB2CHRNA4FFAR1 | |
| SCHEMBL1338113 | 0.87 | TACR1 (0.48) | TACR1DPP4CHRNB2CHRNA4FFAR1 | |
| SCHEMBL8125619 | 0.85 | FFAR1 (0.46) | TACR1DPP4CHRNB2CHRNA4FFAR1 | |
| SCHEMBL3465996 | 0.85 | FFAR1 (0.46) | TACR1DPP4CHRNB2CHRNA4FFAR1 | |
| SCHEMBL2345310 | 0.85 | CD274 (0.43) | TACR1DPP4CHRNB2CHRNA4PDCD1 | |
| SCHEMBL27914973 | 0.85 | TACR1 (0.49) | TACR1DPP4CHRNB2CHRNA4PDCD1 | |
| Ether SCHEMBL9719794 | 0.84 | DPP4 (0.50) | TACR1DPP4PDCD1CD274FFAR1 | |
| SCHEMBL9338655 | 0.83 | TACR1 (0.58) | TACR1DPP4CHRNB2CHRNA4PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003616-B | Epoxy resin composition and cured product thereof | 日铁化学材料株式会社 | 2024-01-09 | — | — | CN | disclosed |
| CN-116348522-A | Alkali-soluble resin containing polymerizable unsaturated group, photosensitive resin composition containing the resin as essential component, and cured product thereof | 日铁化学材料株式会社 | 2023-06-27 | — | — | CN | disclosed |
| CN-115836101-A | Curable resin, curable resin composition, and cured product | DIC株式会社 | 2023-03-21 | — | — | CN | disclosed |
| CN-114989376-A | Phenolic resin, epoxy resin and condensate thereof | 上海衡封新材料科技有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-110922717-A | Epoxy resin composition, prepreg, laminate, and printed wiring board | 日铁化学材料株式会社 | 2020-03-27 | — | — | CN | disclosed |
| US-20120232062-A1 | AZAINDAZOLES TO TREAT FLAVIVIRIDAE VIRUS INFECTION | EIGER BIOPHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-7687459-B2 | Arylalkoxyl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090041721-A1 | serine protease inhibitors; interferons | ENANTA PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-7226950-B2 | Sodium channel modulators | THERAVANCE, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-5780571-A | RESIN OBTAINED BY CONDENSATION OF NAPHTHOL AND 4,4*-BIS/CHLOROMETHYL/BIPHENYL, OPTIONALLY REACTED WITH EPICHLOROHYDRIN | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1998-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232062-A1 | AZAINDAZOLES TO TREAT FLAVIVIRIDAE VIRUS INFECTION | HAVCR2, AZI2, ZC3HAV1 | TACR1 3695/4885DPP4 343/4885CHRNB2 4761/4885 |
| US-20090041721-A1 | serine protease inhibitors; interferons | PRSS1, SERPINB1, SPINT2 | TACR1 1182/4885DPP4 16/4885CHRNB2 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.